Pharmaceutical Industry Information Portal

HomeDiscovery and Development

Discovery and Development

Novavax Covid-19 Vaccine demonstrates 90,4% Effective in Late-stage Trial

Biotech company Novavax said that its COVID-19 vaccine is 90.4% effective in a late-stage trial of nearly 30,000 people in the U.S. and Mexico

Sputnik V demonstrates 94.3% efficacy during the vaccination campaign in Bahrain

An efficacy study was conducted in Bahrain in accordance with WHO guidelines involving more than 5,000 subjects. Overall efficacy beyond 14 days after administering the second dose was estimated at 94.3%.

AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial

American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical trial to evaluate safety of...

NUST MISIS scientists have created nanohybrids for targeted control of infection hotspots

Scientists claim the nanoparticles obtained can carry an increased antibiotic "load" and easily penetrate tissues from the bloodstream and back, ensuring continuous drug delivery to the site of infection.

Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine...

NUST MISIS: Bioactive Implant Coatings Resistant to Most Bacterial Strains Are Obtained in Russia

Young scientists from NUST MISIS have presented multilayer antibacterial coatings with a prolonged effect and a universal spectrum of action. The coating is based...
spot_img

Expert Articles

spot_img